Investor Presentation
61
Investor presentation
First six months of 2022
Novo NordiskⓇ
Patient access to AOM is improving with around 80% commercial
formulary access in the US and 15 countries in IO
WegovyⓇ Patient Access Pathway in NAO
People with obesity¹
Obesity prevalence
in adults
~100 M
Restricted reimbursement for SaxendaⓇ is progressing
EXAMPLES
Commercially covered
~60 M
(+)
WegovyⓇ
formulary access
>40 M
Estimated WegovyⓇ
employer opt-ins
~20 M
~125k
米
BMI > 30
with one co-morbidity
BMI > 35
With pre-diabetes and risk of CV
~60% coverage by private insurance, 20% of
which includes restricted/unrestricted coverage
SaxendaⓇ reimbursed in April 2020 in selected
patient groups
SaxendaⓇ now launched in 65 countries with 16 countries
offering restricted reimbursement; 9 have come in the
last 2 years
Note: Obesity is defined as BMI > 30.
people on WegovyⓇ today
1 Prevalence: Adult obesity facts. Centers for Disease Control and Prevention. Accessed Mar 2021. https://www.cdc.gov/obesity/data/adult.html; US Census Bureau. QuickFacts: United States. Accessed Mar, 2021.
https://www.census.gov/quickfacts/fact/table/US#viewtop.View entire presentation